Literature DB >> 24525209

Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.

Paul Flechsig1, Clemens Kratochwil, Lawrence H Schwartz, Daniel Rath, Jan Moltz, Gerald Antoch, Claus-Peter Heussel, Michael Rieser, Arne Warth, Heike Zabeck, Hans-Ulrich Kauczor, Uwe Haberkorn, Frederik L Giesel.   

Abstract

UNLABELLED: Lung cancer often coexists with acute and chronic lung diseases such as chronic obstructive pulmonary disease. Therefore, mediastinal lymph nodes may be false-positive on (18)F-FDG PET because of the inflammatory disease alone. Nevertheless, (18)F-FDG PET/CT is the primary imaging modality used for staging patients with lung cancer, including nodal status. The purpose of this study was to evaluate whether volumetric CT histogram analysis can improve the characterization of lymph nodes on PET/CT staging of patients with lung cancer.
METHODS: Sixty histologically proven lymph nodes of 45 patients aged 43-76 y diagnosed with lung cancer were investigated. (18)F-FDG PET/CT, contrast-enhanced CT, and nonenhanced CT were performed before surgery or biopsy as part of the clinical staging procedure. Lymph nodes were analyzed on the basis of the (18)F-FDG standardized uptake value and volumetric CT histogram analysis. These findings were correlated to the gold standard of histopathology.
RESULTS: Histologic examination revealed 36 positive and 24 negative lymph nodes, which were also successfully analyzed by volumetric CT histogram. Median CT density was significantly higher for histologically positive lymph nodes (33.2 Hounsfield units [HU]; range, -29.8 to 59.1) than for histologically negative lymph nodes (10.1 HU; range, -21.0 to 87.4; P = 0.002). The incidence of malignancy was 88% above a cutoff value of 20 HU in the ten (18)F-FDG-equivocal lymph nodes; the incidence of benign findings was 100% in the interval between -20 and +20 HU. Visual- and density-based analysis on contrast-enhanced CT failed to differentiate affected from nonaffected lymph nodes.
CONCLUSION: Three-dimensional histogram analysis is a promising and potentially valuable imaging surrogate for N-stage stratification in patients with lung cancer with unclear glucose uptake during (18)F-FDG PET imaging. In cases of equivocal (18)F-FDG PET status, this technique might potentially bridge the diagnostic gap between noninvasive techniques and invasive lymph node sampling and could help improve the yield of core biopsies.

Entities:  

Keywords:  FDG/PET-CT; computed tomography; lung cancer; staging

Mesh:

Substances:

Year:  2014        PMID: 24525209     DOI: 10.2967/jnumed.113.128504

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Authors:  Paul Flechsig; Peter Choyke; Clemens Kratochwil; Arne Warth; Gerald Antoch; Tim Holland Letz; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

2.  PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide.

Authors:  Paul Flechsig; Thomas Lindner; Anastasia Loktev; Saskia Roesch; Walter Mier; Max Sauter; Michael Meister; Christel Herold-Mende; Uwe Haberkorn; Annette Altmann
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

3.  Role of CT Density in PET/CT-Based Assessment of Lymphoma.

Authors:  Paul Flechsig; Christina Walker; Clemens Kratochwil; Laila König; Andrei Iagura; Jan Moltz; Tim Holland-Letz; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

4.  Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.

Authors:  Paul Flechsig; Philipp Frank; Clemens Kratochwil; Gerald Antoch; Daniel Rath; Jan Moltz; Michael Rieser; Arne Warth; Hans-Ulrich Kauczor; Lawrence H Schwartz; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

5.  Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Authors:  Paul Flechsig; Ramin Rastgoo; Clemens Kratochwil; Ole Martin; Tim Holland-Letz; Alexander Harms; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

6.  Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.

Authors:  D Marquez-Medina; A Martin-Marco; S Popat
Journal:  Clin Transl Oncol       Date:  2015-07-24       Impact factor: 3.405

7.  The diagnostic ability of 18F-FDG PET/CT for mediastinal lymph node staging using 18F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer.

Authors:  Jeong Won Lee; Eun Young Kim; Dae Joon Kim; Jae-Hoon Lee; Won Jun Kang; Jong Doo Lee; Mijin Yun
Journal:  Eur Radiol       Date:  2016-03-04       Impact factor: 5.315

8.  Pulmonary ground-glass nodules diagnosis: mean change rate of peak CT number as a discriminative factor of pathology during a follow-up.

Authors:  Mingzheng Peng; Zhao Li; Haiyang Hu; Sida Liu; Binbin Xu; Wenzhuo Zhu; Yudong Han; Liwen Xiong; Qiang Lin
Journal:  Br J Radiol       Date:  2015-11-12       Impact factor: 3.039

9.  Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Authors:  Paul Flechsig; Olena Hural; Michael Kreuter; Martin Eichhorn; Gudula HEUßEL; Christos Sachpekidis; Hans-Ulrich Kauczor; Uwe Haberkorn; Claus Peter Heussel; Monika Eichinger
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

10.  Pre-Operative Prediction of Mediastinal Node Metastasis Using Radiomics Model Based on 18F-FDG PET/CT of the Primary Tumor in Non-Small Cell Lung Cancer Patients.

Authors:  Kai Zheng; Xinrong Wang; Chengzhi Jiang; Yongxiang Tang; Zhihui Fang; Jiale Hou; Zehua Zhu; Shuo Hu
Journal:  Front Med (Lausanne)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.